Analyst picks & changes

Univax Biologics Inc.


Robertson, Stephens' Hurwitz also reiterated a "buy" following FDA approval of the Rockville, Md., company's

WinRho SD

virally inactivated immune globulin (see BioCentury Extra, March 28). As a stand-alone asset, WinRho is worth $9-10 a share, making the rest of UNVX's promising pipeline a virtual

Read the full 508 word article

How to gain access

Continue reading with a
two-week free trial.